Roth Capital analyst Tony Butler upgraded TCR2 Therapeutics (NASDAQ: TCRR) from Neutral to Buy with a price target of $35.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE